Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion

Second Trimester Abortion Clinical Trial

Official title:

Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03044093
• Other study ID #: 0299-16-RMB
• Status: Recruiting
• Phase: Phase 4
• First received: January 18, 2017
• Last updated: February 2, 2017
• Start date: January 2017
• Est. completion date: January 2019

Study information

• Verified date: February 2017
• Source: Rambam Health Care Campus
• Contact: MEIR NIZRI, MD
• Phone: 972-50-2061521
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion - a Double Blinded Randomized Controlled Trial

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• healthy

• no allergy known to these drugs

• second trimester abortion

Exclusion Criteria:

• hematology diseases

• clotting factor deficiency

Related Conditions & MeSH terms

• Second Trimester Abortion

Intervention

Drug:
• Mifepristone
The group that will get in addition to Misoprostol also Mifepristone
• Placebo
The group that will only get Misoprostol
• Misoprostol
Both groups will get think drug

Locations

Country	Name	City	State
Israel	Rambam Medical Campus	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Hospital Stay Duration	number of days of hospital stay	Up to 24 months